Lexpos News

/Lexpos News/

National Patient Safety Alert: Class 1 Medicines Recall Notification: Recall of Quetiapine Oral Suspension (unlicensed medicine), manufactured by Eaststone Limited

Eaststone Limited is initiating a recall of all batches of quetiapine oral suspension products due to a potential risk of overdose, which could have consequences for the safety of patients. This alert is for action by: ​primary and secondary care, specifically those involved in pharmacy services, including dispensing general practices and those involved in the prescribing for mental health conditions. This is [...]

The post National Patient Safety Alert: Class 1 Medicines Recall Notification: Recall of Quetiapine Oral Suspension (unlicensed medicine), manufactured by Eaststone Limited appeared first on Community Pharmacy England.

By |January 29th, 2026|Lexpos News|Comments Off on National Patient Safety Alert: Class 1 Medicines Recall Notification: Recall of Quetiapine Oral Suspension (unlicensed medicine), manufactured by Eaststone Limited

MHRA Drug Safety Update: GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Drug Safety Alert regarding Glucagon-Like Peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. The product information for all GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists (dulaglutide, exenatide, liraglutide, semaglutide and tirzepatide) has been further updated to highlight the potential [...]

The post MHRA Drug Safety Update: GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings appeared first on Community Pharmacy England.

By |January 29th, 2026|Lexpos News|Comments Off on MHRA Drug Safety Update: GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings

NHSBSA ‘Hints & Tips’ – Issue 62

The NHS Business Services Authority (NHSBSA) produces a quarterly newsletter called “Hints & Tips for dispensing contractors”. The latest edition (Issue 62) contains some useful information and advice on: New address for end of month batch submissions Pharmacy Quality Scheme: Declaration window opens in Manage Your Service on 2 February 2026 Pharmacy Quality Scheme: Antimicrobial [...]

The post NHSBSA ‘Hints & Tips’ – Issue 62 appeared first on Community Pharmacy England.

By |January 29th, 2026|Lexpos News|Comments Off on NHSBSA ‘Hints & Tips’ – Issue 62

January 2026 Price Concessions 3rd Update

The Department of Health and Social Care (DHSC) has today (29/01/2026) confirmed the following list of price concessions for January 2026: Drug Pack size Price concession Aspirin 75mg tablets 28 £2.95 Chloramphenicol 0.5% eye drops 10 £2.75 Cimetidine 400mg tablets 60 £5.58 Co-codamol 30mg/500mg capsules 100 £5.68 Diclofenac sodium 50mg gastro-resistant tablets 28 £6.86 Glycerol [...]

The post January 2026 Price Concessions 3rd Update appeared first on Community Pharmacy England.

By |January 29th, 2026|Lexpos News|Comments Off on January 2026 Price Concessions 3rd Update

Pharmacies’ vital dispensing role under threat without urgent action

A new report has highlighted the vital, yet underappreciated role that community pharmacy dispensing plays in the NHS and across communities nationwide. The report, by the Company Chemists’ Association (CCA), sets out how community pharmacy dispensing is the backbone of accessible, safe, and equitable healthcare, but is under unsustainable pressure. Pharmacies’ vital dispensing role under [...]

The post Pharmacies’ vital dispensing role under threat without urgent action appeared first on Community Pharmacy England.

By |January 29th, 2026|Lexpos News|Comments Off on Pharmacies’ vital dispensing role under threat without urgent action